References
- 1
Prospective Studies Collaboration .
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses
of 57 prospective studies.
Lancet.
2009;
373
1083-1096
- 2
Pischon T, Boeing H, Hoffmann K. et al .
General and abdominal adiposity and risk of death in Europe.
N Engl J Med.
2008;
359
2105-2120
- 3
Mathus-Vliegen E M.
The role of endoscopy in bariatric surgery.
Best Pract Res Clin Gastroenterol.
2008;
22
839-864
- 4
Christou N V, Sampalis J S, Liberman M. et al .
Surgery decreases long-term mortality, morbidity, and health care use in morbidly
obese patients.
Ann Surg.
2004;
240
416-423
- 5
Stellato T A, Crouse C, Hallowell P T.
Bariatric surgery: Creating new challenges for the endoscopist.
Gastrointest Endosc.
2003;
57
86-94
- 6
El-Serag H B.
Obesity and disease of the esophagus and colon.
Gastroenterol Clin N Am.
2005;
34
63-82
- 7
Hampel H, Abraham N S, El-Serag H B.
Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications.
Ann Intern Med.
2005;
143
199-211
- 8
Sjostrom L, Larsson B, Backman L. et al .
Swedish obese subjects (SOS). Recruitment for an intervention study and a selected
description of the obese state.
Int J Obes Relat Metab Disord.
1992;
16
465-479
- 9
Weinsier R L, Wilson L J, Lee J.
Medically safe rate of weight loss for the treatment of obesity: a guideline based
on risk of gallstone formation.
Am J Med.
1995;
98
115-117
- 10
Tsai C J, Leitzmann M F, Willett W C, Giovannucci E L.
Prospective study of abdominal adiposity and gallstone disease in US men.
Am J Clin Nutr.
2004;
80
38-44
- 11
Tsai C J, Leitzmann M F, Willett W C, Giovannucci E L.
Weight cycling and risk of gallstone disease in men.
Arch Intern Med.
2006;
166
2369-2374
- 12
Martinez J, Sanchez-Paya J, Palazon J M. et al .
Is obesity a risk factor in acute pancreatitis? A meta-analysis.
Pancreatology.
2004;
4
42-48
- 13
Calle E E.
Obesity and cancer.
BMJ.
2007;
335
1107-1108
- 14
Bergstrom A, Pisani P, Tenet V. et al .
Overweight as an avoidable cause of cancer in Europe.
Int J Cancer.
2001;
91
421-430
- 15
Corley D A.
Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is
the link?.
Gut.
2007;
56
1493-1494
- 16
Kubo A, Corley D A.
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic
review and meta-analysis.
Cancer Epidemiol Biomarkers Prev.
2006;
15
872-878
- 17
Giovannucci E, Michaud D.
The role of obesity and related metabolic disturbances in cancers of the colon, prostate,
and pancreas.
Gastroenterology.
2007;
132
2208-2225
- 18
Berrington de G A, Sweetland S, Spencer E.
A meta-analysis of obesity and the risk of pancreatic cancer.
Br J Cancer.
2003;
89
519-523
- 19
Renehan A G, Tyson M, Egger M. et al .
Body-mass index and incidence of cancer: a systematic review and meta-analysis of
prospective observational studies.
Lancet.
2008;
371
569-578
- 20
Corley D A, Kubo A, Levin T R. et al .
Abdominal obesity and body mass index as risk factors for Barrett’s esophagus.
Gastroenterology.
2007;
133
34-41
- 21
Pischon T, Lahmann P H, Boeing H. et al .
Body size and risk of colon and rectal cancer in the European prospective investigation
into cancer and nutrition (EPIC).
J Natl Cancer Inst.
2006;
98
920-931
- 22
Patel A V, Rodriguez C, Bernstein L. et al .
Obesity, recreational physical activity, and risk of pancreatic cancer in a large
US cohort.
Cancer Epidemiol Biomarkers Prev.
2005;
14
459-466
- 23
Giovannucci E.
Obesity, gender, and colon cancer.
Gut.
2002;
51
147
- 24
Terry P D, Miller A B, Rohan T E.
Obesity and colorectal cancer risk in women.
Gut.
2002;
51
191-194
- 25
Korner J, Leibel R L.
To eat or not to eat – how the gut talks to the brain.
N Engl J Med.
2003;
349
926-928
- 26
Blundell J E.
Perspective on the central control of appetite.
Obesity (Silver Spring).
2006;
14 Suppl 4
160S-163S
- 27
Wren A M, Bloom S R.
Gut hormones and appetite control.
Gastroenterology.
2007;
132
2116-2130
- 28
Monteleone P, Bencivenga R, Longobardi N. et al .
Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal
in healthy women.
J Clin Endocrinol Metab.
2003;
88
5510-5514
- 29
Batterham R L, Heffron H, Kapoor S. et al .
Critical role for peptide YY in protein-mediated satiation and body weight regulation.
Cell Metab.
2006;
4
223-233
- 30
Cummings D E, Shannon M H.
Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss?.
J Clin Endocrin Metab.
2003;
88
2999-3002
- 31
Le Roux C W, Aylwin S J, Batterham R L. et al .
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate
weight loss, and improve metabolic parameters.
Ann Surg.
2006;
243
108-114
- 32
Batterham R L, Cohen M A, Ellis S M. et al .
Inhibition of food intake in obese subjects by peptide YY3–36.
N Engl J Med.
2003;
349
941-948
- 33
Batterham R L, Le R oux, Cohen M A. et al .
Pancreatic polypeptide reduces appetite and food intake in humans.
J Clin Endocrinol Metab.
2003;
88
3989-3992
- 34 World Health Organization .Obesity: preventing and managing the global epidemic.
Report of a WHO Consultation on Obesity, Geneva, 3 – 5 June 1997. Report No.: WHO/NUT/NCD/98.1
- 35
National Institutes of Health, National Heart, Lung and Blood Institute .
Clinical guidelines on the identification, evaluation, and treatment of overweight
and obesity in adults – The evidence report.
Obes Res.
1998;
6 Suppl 2
1S-209S
- 36 National Institute of Clinical Excellence .Obesity: the prevention, identification,
assessment and management of overweight and obesity in adults and children, 2006. http://Available at: www.NICE.org.uk/CG43
- 37
Glenny A M, O’Meara S, Melville A. et al .
The treatment and prevention of obesity: a systematic review of the literature.
Int J Obes Relat Metab Disord.
1997;
21
715-737
- 38
de Goederen-van der Meij S, Pierik R GJM, OudkerkPool M. et al .
Six months of balloon treatment does not predict the success of gastric banding.
Obes Surg.
2007;
17
88-94
- 39
Schapiro M, Benjamin S, Blackburn G. et al .
Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida,
March 19 – 21, 1987.
Gastrointest Endosc.
1987;
33
323-327
- 40
Fernandes M, Atallah A N, Soares B G. et al .
Intragastric balloon for obesity.
Cochrane Database Syst Rev.
2007;
1
CD004931
- 41
Mathus-Vliegen E M.
Intragastric balloon treatment for obesity: what does it really offer?.
Dig Dis.
2008;
26
40-44
- 42
Dumonceau J M.
Evidence-based review of the Bioenterics intragastric balloon for weight loss.
Obes Surg.
2008;
18
1611-1617
- 43
Negrin Dastis S, Francois E, Deviere J. et al .
Intragastric balloon for weight loss: results in 100 individuals followed for at least
2.5 years.
Endoscopy.
2009;
41
575-580
- 44
Melissas J, Mouzas J, Filis D. et al .
The intragastric balloon – smoothing the path to bariatric surgery.
Obes Surg.
2006;
16
897-902
- 45
Rucker D, Padwal R, Li S K. et al .
Long term pharmacotherapy for obesity and overweight: updated meta-analysis.
BMJ.
2007;
335
1194-1199
- 46
Christensen R, Kristensen P K, Bartels E M. et al .
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised
trials.
Lancet.
2007;
370
1706-1713
- 47
Mathus-Vliegen E M, Tytgat G N.
Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy
of 1-year balloon treatment followed by a 1-year balloon-free follow-up.
Gastrointest Endosc.
2005;
61
19-27
- 48
Rutten S JE, de Goederen-van der Meij S, Pierik R GJM, Mathus-Vliegen E MH.
Changes in quality of life after balloon treatment followed by gastric banding in
severely obese patients – the use of two different quality of life questionnaires.
Obes Surg.
2009 ;
DOI: DOI 10.1007/s11695-008-9732-3
E. M. H. Mathus-VliegenMD PhD
Department of Gastroenterology and Hepatology
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
Fax: +31-20-6917033
Email: e.mathus-vliegen@amc.uva.nl
